The CEO of the German drugmaker is pinning some numbers on the medium term; the Big 5 will help Bayer aim for an average of 8% annual growth in its pharma unit through 2016, Marijn Dekkers said Wednesday.
Bayer knows what a good launch can do; with blood thinner Xarelto and eye drug Eylea, it's had a couple of the recent best. Thanks to that pair of hot-selling meds, the German pharma raised the sales forecast for its new products by €2 billion late last week--and it's raising its marketing budget along with it.
Blood thinner Xarelto and eye med Eylea pack a pretty good one-two-punch. Those new drugs helped Bayer's pharma sales climb 9.4% in 2013, and they're not stopping: They'll ultimately lead a group of 5 recently launched products to sales of €7.5 billion ($10.3 billion) or more, CEO Marijn Dekkers said Friday.
Regeneron's hot-selling eye drug Eylea has done a lot in its short life, including post $1.4 billion in 2013 U.S. sales--and make the company's veteran CEO, Len Schleifer, into a billionaire.
After 25 years at the helm of one of biotech's best-case scenarios, Regeneron CEO Leonard Schleifer has crossed the $1 billion threshold, according to Forbes, thanks largely to the company's blockbuster eye drug. And, with a stable of promising late-stage treatments waiting in the wings, the Tarrytown, NY, executive's most profitable work may still be ahead of him.
Yesterday, Regeneron CEO Len Schleifer announced that r ather than the $377 million expected by analysts, Regeneron will report about $400 million in U.S. sales for macular degeneration treatment Eylea in the fourth quarter, Bloomberg reports.
Partners Regeneron and Bayer are hoping to piggy-back on their success with the wet age-related macular degeneration blockbuster Eylea, reuniting to develop a new drug that could become part of a combination therapy for the disease.
Sales of Bayer's Eylea have taken off since the EU greenlighted the eye drug in late in 2012. But now, Germany's cost watchdog has thrown up a roadblock for the second time. Thursday, the German Institute for Quality and Efficiency in Health Care (IQWiG) said it was unable to assess whether Eylea provided an advantage over its rival, Novartis' Lucentis--an opinion that could hurt sales for Bayer on its home turf.
Tarrytown, NY-based Regeneron, maker of the hot-selling vision treatment Eylea, says it will hire 300 people for a new plant in Limerick, Ireland, its first plant outside the U.S., once it finishes refurbishing an abandoned Dell computer facility there.
Bayer has taken another step toward fulfilling blockbuster ambitions for its eye drug Eylea. The German drugmaker asked European regulators to approve the vision-loss treatment for patients with diabetic macular edema. With diabetes on the rise all over the world, the new indication could offer long-term growth for the already fast-rising drug.